» Articles » PMID: 37493940

Insights on Discovery, Efficacy, Safety and Clinical Applications of Ghrelin Receptor Agonist Capromorelin in Veterinary Medicine

Overview
Journal Vet Res Commun
Publisher Springer
Date 2023 Jul 26
PMID 37493940
Authors
Affiliations
Soon will be listed here.
Abstract

Growth hormone and insulin like growth factor-1 plays an important role in the regulation of body composition and metabolism. Growth Hormone is released from the pituitary through a specific G-protein coupled receptor (GPCR) called growth hormone secretagogue receptor 1a expressed in the hypothalamus. Ghrelin is a peptide hormone released from the cells in the stomach, which stimulates appetite and food intake in mammals, regulates gut motility, gastric acid secretion, taste sensation, circadian rhythm, learning and memory, oxidative stress, autophagy, glucose metabolism etc. When the release of the endogenous ligand GHSR-1a, i.e., ghrelin is malfunctioned or stopped, external substitutes are administrated to induce the stimulation of growth hormone and appetite. A class of compound known as ghrelin receptor agonists are developed as an external substitute of ghrelin for regulation and stimulation of growth hormone in frailty, for body weight gain, muscle mass gain, prevention of cachexia and for the treatment of chronic fatigue syndromes. Capromorelin [Entyce™ (Aratana Therapeutics, Leawood, KS, USA)] is the only FDA (Food and Drug Administration) approved (May 2016) drug used for stimulating appetite in dogs and was marketed in the fall of 2017. In 2020, USFDA approved Capromorelin [Elura™ (Elanco US Inc.)] for the management of weight loss in chronic kidney disease of cats. This article reviews the discovery of the ghrelin receptor agonist capromorelin, its efficacy, safety, clinical applications and aims to delineate its further scope of use in veterinary practice.

Citing Articles

Complete mitochondrial genome sequence analysis revealed double matrilineal components in Indian Ghoongroo pigs.

Das P, Kumar S, Choudhury M, Pegu S, Meera K, Deb R Sci Rep. 2025; 15(1):2219.

PMID: 39820257 PMC: 11739383. DOI: 10.1038/s41598-024-81205-4.

References
1.
Agnew W, Korman R . Pharmacological appetite stimulation: rational choices in the inappetent cat. J Feline Med Surg. 2014; 16(9):749-56. PMC: 11185246. DOI: 10.1177/1098612X14545273. View

2.
Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A . Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002; 159(6):1029-37. PMC: 2173981. DOI: 10.1083/jcb.200207165. View

3.
Beiras-Fernandez A, Kreth S, Weis F, Ledderose C, Pottinger T, Dieguez C . Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides. 2010; 31(12):2222-8. DOI: 10.1016/j.peptides.2010.08.019. View

4.
Bowers C . Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1999; 54(12):1316-29. PMC: 11147263. DOI: 10.1007/s000180050257. View

5.
Bowers C, Momany F, REYNOLDS G, Chang D, Hong A, Chang K . Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology. 1980; 106(3):663-7. DOI: 10.1210/endo-106-3-663. View